An update on inhibitors of human 14 kDa Type II s-PLA2 in development

Curr Pharm Des. 2001 Feb;7(3):181-98. doi: 10.2174/1381612013398275.

Abstract

Recent progress in the development of inhibitors of human Type II s-PLA2 as potential anti-inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY-315920 (S-5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY-315920 is extensively reviewed, as well as the current status of other small molecular weight inhibitors of Type II s-PLA2 that have been reported to be in late-stage development

Publication types

  • Review

MeSH terms

  • Acetates / pharmacology
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / chemistry
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Drug Design*
  • Group II Phospholipases A2
  • Humans
  • Indoles / pharmacology
  • Keto Acids
  • Molecular Structure
  • Patents as Topic
  • Phospholipases A / antagonists & inhibitors*
  • Phospholipases A / chemistry
  • Phospholipases A2
  • Sulfonamides / pharmacology
  • Tretinoin / analogs & derivatives*
  • Tretinoin / pharmacology

Substances

  • Acetates
  • Anti-Inflammatory Agents, Non-Steroidal
  • Indoles
  • Keto Acids
  • SB 203347
  • Sulfonamides
  • 13-cis-12-(3'-carboxyphenyl)retinoic acid
  • varespladib
  • Tretinoin
  • Phospholipases A
  • Group II Phospholipases A2
  • Phospholipases A2